Macrophages and galectin 3 play critical roles in CVB3-induced murine acute myocarditis and chronic fibrosis

Journal of Molecular and Cellular Cardiology

Volumn 85, Issue , 2015, Pages 58-70

  De Giusti, Carolina Jaquenod ^a   Ure, Agustín E ^a   Rivadeneyra, Leonardo ^b   Schattner, Mirta ^b   Gomez, Ricardo M ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Instituto de Medicina Experimental CONICET ANM   (Argentina)

Author keywords

Coxsackievirus B3; Fibrosis; Galectin 3; Macrophages; Myocarditis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; MESSENGER RNA; N ACETYLGALACTOSAMINE;

ACUTE DISEASE; ALPHASMA GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CHRONIC DISEASE; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; COXSACKIEVIRUS B3; GAL3 GENE; GENE DISRUPTION; GENE EXPRESSION REGULATION; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MACROPHAGE FUNCTION; MALE; MOUSE; MYOFIBROSIS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD; VIRUS MYOCARDITIS; VIRUS REPLICATION; ANIMAL; C3H MOUSE; C57BL MOUSE; CELL LINE; COMPLICATION; ENTEROVIRUS; FIBROSIS; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; MYOCARDITIS; PHYSIOLOGY; VIROLOGY;

COXSACKIEVIRUS; MURINAE; MUS;

ANIMALS; CELL LINE; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; FIBROSIS; GALECTIN 3; MACROPHAGES; MALE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDITIS;

EID: 84930225307     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.05.010     Document Type: Article

References (63)

1. Stanway G., Brown F., Christian P., Hovi T., Hyypiä T., King A.M.Q., et al. Picornaviridae. Virus taxonomy, VIIIth report of the ICTV 2004, 757-778. Elsevier, London, United Kingdom. C.M. Fauquet, M.A. Mayo, J. Maniloff, U. Desselberger, L.A. Ball (Eds.).
2. Fairweather D., Stafford K.A., Sung Y.K. Update on coxsackievirus B3 myocarditis. Curr Opin Rheumatol 2012, 24:401-407.
3. Andreoletti L. Viral myocarditis: physiopathology and diagnosis. Myocarditis: InTech 2011, D. Cihakova (Ed.).
4. Szalay G., Sauter M., Haberland M., Zuegel U., Steinmeyer A., Kandolf R., et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 2009, 104:851-859.
5. Kindermann I., Barth C., Mahfoud F., Ukena C., Lenski M., Yilmaz A., et al. Update on myocarditis. J Am Coll Cardiol 2012, 59:779-792.
6. Gauntt C., Huber S. Coxsackievirus experimental heart diseases. Front Biosci 2003, 8:e23-e35.
7. Gomez R.M., Castagnino C.G., Berria M.I. Extracellular matrix remodelling after coxsackievirus B3-induced murine myocarditis. Int J Exp Pathol 1992, 73:643-653.
8. Shinagawa H., Frantz S. Cellular immunity and cardiac remodeling after myocardial infarction: role of neutrophils, monocytes, and macrophages. Curr Heart Fail Rep 2015, 12:247-254.
9. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-692.
10. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
11. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 122:787-795.
12. van Rooijen N., Hendrikx E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 2010, 605:189-203.
13. Heim A., Zeuke S., Weiss S., Ruschewski W., Grumbach I.M. Transient induction of cytokine production in human myocardial fibroblasts by coxsackievirus B3. Circ Res 2000, 86:753-759.
14. Lindner D., Li J., Savvatis K., Klingel K., Blankenberg S., Tschope C., et al. Cardiac fibroblasts aggravate viral myocarditis: cell specific coxsackievirus B3 replication. Mediators Inflamm 2014, 2014:519528.
15. Ma F., Li Y., Jia L., Han Y., Cheng J., Li H., et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 2012, 7. e35144.
16. Liu F.T., Rabinovich G.A. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci 2010, 1183:158-182.
17. de Boer R.A., Lok D.J., Jaarsma T., van der Meer P., Voors A.A., Hillege H.L., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
18. de Boer R.A., Yu L., van Veldhuisen D.J. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010, 7:1-8.
19. Sharma U., Rhaleb N.E., Pokharel S., Harding P., Rasoul S., Peng H., et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 2008, 294:H1226-H1232.
20. Li L.C., Li J., Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 2014, 351:336-343.
21. Cifuente J.O., Ferrer M.F., Jaquenod De Giusti C., Song W.C., Romanowski V., Hafenstein S.L., et al. Molecular determinants of disease in coxsackievirus B1 murine infection. J Med Virol 2011, 83:1571-1581.
22. Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 1996, 70:7811-7818.
23. Yu L., Ruifrok W.P., Meissner M., Bos E.M., van Goor H., Sanjabi B., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
24. Ferrer M.F., Pascuale C.A., Gomez R.M., Leguizamon M.S. DTU I isolates of Trypanosoma cruzi induce upregulation of galectin-3 in murine myocarditis and fibrosis. Parasitology 2014, 141:849-858.
25. Austyn J.M., Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981, 11:805-815.
26. Negrotto S., Jaquenod De Giusti C., Rivadeneyra L., Ure A.E., Mena H.A., Schattner M., et al. Platelets interact with coxsackieviruses B and have a critical role in the pathogenesis of virus-induced myocarditis. J Thromb Haemost 2015, 13:271-282.
27. Henderson N.C., Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009, 230:160-171.
28. Chow L.H., Gauntt C.J., McManus B.M. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab Invest 1991, 64:55-64.
29. Takemura G., Fujiwara H., Takatsu Y., Fujiwara T., Nakao K. Venticular expression of atrial and brain natriuretic peptides in patients with myocarditis. Int J Cardiol 1995, 52:213-222.
30. Fairweather D., Abston E.D., Coronado M.J. Biomarkers of heart failure in myocarditis and dilated cardiomyopathy. Myocarditis: InTech 2011, D. Cihakova (Ed.).
31. Rager-Zisman B., Allison A.C. The role of antibody and host cells in the resistance of mice against infection by coxsackie B-3 virus. J Gen Virol 1973, 19:329-338.
32. van Rooijen N., Sanders A. Elimination, blocking, and activation of macrophages: three of a kind?. J Leukoc Biol 1997, 62:702-709.
33. Frantz S., Nahrendorf M. Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc Res 2014, 102:240-248.
34. Salazar-Mather T.P., Orange J.S., Biron C.A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 1998, 187:1-14.
35. Lim J.K., Obara C.J., Rivollier A., Pletnev A.G., Kelsall B.L., Murphy P.M. Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol 2011, 186:471-478.
36. Aldridge J.R., Moseley C.E., Boltz D.A., Negovetich N.J., Reynolds C., Franks J., et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009, 106:5306-5311.
37. Tate M.D., Pickett D.L., van Rooijen N., Brooks A.G., Reading P.C. Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice. J Virol 2010, 84:7569-7580.
38. Hirasawa K., Tsutsui S., Takeda M., Mizutani M., Itagaki S., Doi K. Depletion of Mac1-positive macrophages protects DBA/2 mice from encephalomyocarditis virus-induced myocarditis and diabetes. J Gen Virol 1996, 77(Pt 4):737-741.
39. Deguchi H., Kitaura Y., Hayashi T., Kotaka M., Kawamura K. Cell-mediated immune cardiocyte injury in viral myocarditis of mice and patients. Jpn Circ J 1989, 53:61-77.
40. Godeny E.K., Gauntt C.J. In situ immune autoradiographic identification of cells in heart tissues of mice with coxsackievirus B3-induced myocarditis. Am J Pathol 1987, 129:267-276.
41. Chow L.H., Beisel K.W., McManus B.M. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 1992, 66:24-31.
42. Gomez R.M., Rinehart J.E., Wollmann R., Roos R.P. Theiler's murine encephalomyelitis virus-induced cardiac and skeletal muscle disease. J Virol 1996, 70:8926-8933.
43. Vella C., Festenstein H. Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection. J Gen Virol 1992, 73:1379-1386.
44. Yuan J., Liu Z., Lim T., Zhang H., He J., Walker E., et al. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 2009, 104:628-638.
45. Matsui S., Matsumori A., Matoba Y., Uchida A., Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 1994, 94:1212-1217.
46. Laskin D.L., Sunil V.R., Gardner C.R., Laskin J.D. Macrophages and tissue injury: agents of defense or destruction?. Annu Rev Pharmacol Toxicol 2011, 51:267-288.
47. Wessely R., Klingel K., Santana L.F., Dalton N., Hongo M., Jonathan Lederer W., et al. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest 1998, 102:1444-1453.
48. Klingel K., Hohenadl C., Canu A., Albrecht M., Seemann M., Mall G., et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A 1992, 89:314-318.
49. Klingel K., Stephan S., Sauter M., Zell R., McManus B.M., Bultmann B., et al. Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J Virol 1996, 70:8888-8895.
50. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 115:56-65.
51. Sung S.A., Jo S.K., Cho W.Y., Won N.H., Kim H.K. Reduction of renal fibrosis as a result of liposome encapsulated clodronate induced macrophage depletion after unilateral ureteral obstruction in rats. Nephron Exp Nephrol 2007, 105:e1-e9.
52. Henderson N.C., Mackinnon A.C., Farnworth S.L., Kipari T., Haslett C., Iredale J.P., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008, 172:288-298.
53. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
54. Breuilh L., Vanhoutte F., Fontaine J., van Stijn C.M., Tillie-Leblond I., Capron M., et al. Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect Immun 2007, 75:5148-5157.
55. Sato S., Ouellet M., St-Pierre C., Tremblay M.J. Glycans, galectins, and HIV-1 infection. Ann N Y Acad Sci 2012, 1253:133-148.
56. Mishra B.B., Li Q., Steichen A.L., Binstock B.J., Metzger D.W., Teale J.M., et al. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One 2013, 8. e59616.
57. Henderson N.C., Mackinnon A.C., Farnworth S.L., Poirier F., Russo F.P., Iredale J.P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006, 103:5060-5065.
58. Woodward A.M., Mauris J., Argueso P. Binding of transmembrane mucins to galectin-3 limits herpesvirus 1 infection of human corneal keratinocytes. J Virol 2013, 87:5841-5847.
59. Pais-Correia A.M., Sachse M., Guadagnini S., Robbiati V., Lasserre R., Gessain A., et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2010, 16:83-89.
60. Colnot C., Ripoche M.A., Milon G., Montagutelli X., Crocker P.R., Poirier F. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 1998, 94:290-296.
61. Hsu D.K., Yang R.Y., Pan Z., Yu L., Salomon D.R., Fung-Leung W.P., et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000, 156:1073-1083.
62. de Boer R.A., van der Velde A.R., Mueller C., van Veldhuisen D.J., Anker S.D., Peacock W.F., et al. Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther 2014, 28:237-246.
63. Garber K. Galecto biotech. Nat Biotechnol 2013, 31:481.